Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-stage tumor types from three phase I/II trials of durvalumab (± the anti-CTLA4 therapy tremelimumab). Higher pretreatment variant allele frequencies (VAF) were associated with poorer overall survival (OS) and other known prognostic factors, but not objective response, suggesting a prognostic role for patient outcomes. On-treatment reductions in VAF and lower on-treatment VAF were independently associated with longer progression-free survival and OS and increased objective response rate, but not prognostic variables, suggesting that on-treatment ctDNA dynamics are predictive of benefit from immune checkpoint blockade. Accordingly, we propose a concept of “molecular response” using ctDNA, incorporating both pretreatment and on-treatment VAF, that predicted long-term survival similarly to initial radiologic response while also permitting early differentiation of responders among patients with initially radiologically stable disease. Significance: In a pan-cancer analysis of immune checkpoint blockade, pretreatment ctDNA levels appeared prognostic and on-treatment dynamics predictive. A “molecular response” metric identified long-term responders and adjudicated benefit among patients with initially radiologically stable disease. Changes in ctDNA may be more dynamic than radiographic changes and could complement existing trial endpoints. This article is highlighted in the In This Issue feature, p. 1775
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, integration of longitudinal blood-based assays such as circulating-tumor DNA (ctDNA; ref. 216), which are easier to implement and less invasive as opposed to longitudinal tumor biopsies, is under investigation as a method to monitor responses to ICT.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Self-citationAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Items 101–200 of 376
Gray, J. E., Thompson, J. C., Carpenter, E. L., Elkhouly, E., & Aggarwal, C. (2021) · The Oncologist · doi:10.1002/onco.13889 · Cited by 29
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 28
Du, F., & Liu, Y. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24141 · Cited by 28
Frank, M. S., Andersen, C. S. A., Ahlborn, L. B., Pallisgaard, N., Bødtger, U. C. S., & Gehl, J. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0258 · Cited by 28
Zhou, Y., Wang, R., Zeng, M., & Liu, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1551219 · Cited by 26
Gristina, V., Barraco, N., Mantia, M. L., Castellana, L., Insalaco, L., Bono, M., Perez, A., Sardo, D., Inguglia, S., Iacono, F., et al. (2022) · Cancers · doi:10.3390/cancers14236013 · Cited by 25
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Nigro, M. C., Marchese, P. V., Deiana, C., Casadio, C., Galvani, L., Federico, A. D., & Giglio, A. D. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s388047 · Cited by 25
Ernst, S. M., van Marion, R., Atmodimedjo, P. N., de Jonge, E., Mathijssen, R. H. J., Paats, M. S., de Bruijn, P., Koolen, S. L., von der Thüsen, J. H., Aerts, J. G. J. V., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.04.007 · Cited by 24
Liu, H., Chen, J., Huang, Y., Zhang, Y., Ni, Y., Xu, N., Zhao, F., Tang, Y., Liu, H., Sun, G., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001372 · Cited by 24
The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers
Lee, M. S., Kaseb, A. O., & Pant, S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3626 · Cited by 24
Biomarkers and experimental models for cancer immunology investigation
Xu, H., Jia, Z., Liu, F., Li, J., Huang, Y., Jiang, Y., Pu, P., Shang, T., Tang, P., Zhou, Y., et al. (2023) · MedComm · doi:10.1002/mco2.437 · Cited by 24
Hsiehchen, D., Kainthla, R., Kline, H., Siglinsky, E., Ahn, C. W., & Zhu, H. (2025) · Nature Communications · doi:10.1038/s41467-025-60757-7 · Cited by 24
Zang, J., Zhang, R., Jin, D., Xie, F., Shahatiaili, A., Wu, G., Zhang, Y., Zhao, Z., Du, P., Jia, S., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6166 · Cited by 24
Kato, S., Li, B., Adashek, J. J., Cha, S. W., Bianchi-Frias, D., Qian, D., Kim, L., so, T. W., Mitchell, M., Kamei, N., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2052410 · Cited by 24
Hepatic Clearance of Cell-Free DNA: Possible Impact on Early Metastasis Diagnosis
Khier, S., & Gahan, P. B. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00554-2 · Cited by 24
Cescon, D. W., Hilton, J. F., Morales, S. M., Layman, R. M., Pluard, T., Yeo, B. J., Park, I. H., Provencher, L., Kim, S., Im, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0133 · Cited by 24
Self-citationAppropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA
Sunami, K., Bando, H., Yatabe, Y., Naito, Y., Takahashi, H. E., Tsuchihara, K., Toyooka, S., Mimori, K., Kohsaka, S., Uetake, H., et al. (2021) · Cancer Science · doi:10.1111/cas.15022 · Cited by 24
Ding, H., Yuan, M., Yang, Y., & Xu, S. X. (2024) · Nature Communications · doi:10.1038/s41467-024-51316-7 · Cited by 23
Liang, S. I., Quandt, Z., Wienke, S., Wang, J., Gordon, S., Barnett, R. M., Masannat, J., Chang, K., Espenschied, C. R., Quinn, K., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0151 · Cited by 23
Zhang, H., Ren, Y., Wang, F., Tu, X., Tong, Z., Liu, L., Zheng, Y., Zhao, P., Cheng, J., Li, J., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00807-2 · Cited by 23
Bui, N. Q., Nemat‐Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, C. R., Wang, D. S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0250 · Cited by 23
Zhang, Y., Zou, Q., Zhao, B., Su, N., Li, Z., Wang, X., Liu, P., Tian, X., Fang, X., Cai, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101833 · Cited by 23
Galant, N., Nicoś, M., Kuźnar-Kamińska, B., & Krawczyk, P. A. (2024) · Cancers · doi:10.3390/cancers16040782 · Cited by 22
Moghaddam, A. S., Lu, K. Y., Nasrollahi, E., Oji, L., Homeniuk, A., Amosu, O., Chelysheva, D., & Brufsky, A. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00873-1 · Cited by 21
Guigal, N., Lockhart, B. P., Moser, T., & Heitzer, E. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03328-4 · Cited by 21
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer
Wu, Y.-X., Zhou, X., Wang, J.-Q., Chen, G.-M., Chen, J.-X., Wang, R.-C., Huang, J., & Chen, J. (2023) · Immunotherapy · doi:10.2217/imt-2022-0080 · Cited by 21
Hsiehchen, D., Espinoza, M., Gerber, D. E., & Beg, M. S. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1963166 · Cited by 21
Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy
Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K. J., Vafaee, F., Scott, K. F., Roberts, T. L., Becker, T. M., & SOUZA, P. D. (2022) · Cancers · doi:10.3390/cancers14071669 · Cited by 21
Kansara, M., Bhardwaj, N., Thavaneswaran, S., Xu, C., Lee, J., Chang, L., Madison, R. W., Lin, F. P. Y., Hsu, E., Patel, V., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13349 · Cited by 21
Jiang, R., Xu, C., Li, P., Meng, E., Wu, X., & Wu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-63486-x · Cited by 21
Garmezy, B., Borad, M. J., Bahleda, R., Perez, C. A., Chen, L., Kato, S., Oh, D., Severson, P. L., Tam, B. Y. Y., Quah, C. S., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0137 · Cited by 21
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 21
Yap, T. A., Tan, D. S. P., Stathis, A., Shapiro, G. I., Iwasa, S., Joerger, M., Zhang, J., Plummer, R., Sawyer, M. B., Tan, D. S. W., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1500 · Cited by 20
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Hu, Q., Chen, L., Li, K., Liu, R. M., Sun, L., & Han, T. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1157 · Cited by 20
He, M., Ji, C., Li, Z., Chen, S., Gao, J., Shen, L., & Zhang, C. (2025) · Gastric Cancer · doi:10.1007/s10120-025-01621-x · Cited by 20
Wu, J., Zhang, S., Yu, S., An, G., Wang, Y., Yu, Y., Liang, L., Wang, Y., Xu, X., Xiong, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53109-4 · Cited by 19
Wijetunga, N. A., Goglia, A. G., Weinhold, N., Berger, M. F., Cislo, M., Higginson, D. S., Chabot, K., Osman, A. M., Schaff, L. R., Pentsova, E. I., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2434 · Cited by 19
Monette, A., Warren, S., Barrett, J. C., Garnett‐Benson, C., Schalper, K. A., Taube, J. M., Topp, B. G., & Snyder, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009427 · Cited by 19
Self-citationCha, Y., Kim, S., & Han, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.446 · Cited by 19
Ruiz‐Torres, D. A., Merkin, R. D., Bryan, M. E., Mendel, J., Efthymiou, V., Roberts, T. J., Patel, M. J., Park, J. C., Chevalier, A., Murray, C., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01084-4 · Cited by 19
Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient
Hemenway, G., Anker, J. F., Riviere, P. J., Rose, B. S., Galsky, M. D., & Ghatalia, P. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432054 · Cited by 19
Biomarkers of immunotherapy response in breast cancer beyond PD-L1
Chic, N., Brasó‐Maristany, F., & Prat, A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06421-2 · Cited by 18
Lu, C., Zhang, Y., Chen, Z., Zhou, Q., & Wu, Y.-L. L. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836891 · Cited by 18
Advances in the Management of Early-Stage Triple-Negative Breast Cancer
Bhardwaj, P. V., Wang, Y., Brunk, E., Spanheimer, P. M., & Abdou, Y. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512478 · Cited by 18
Koh, Y., Nakano, K., Katayama, K., Yamamichi, G., Yumiba, S., Tomiyama, E., Matsushita, M., Hayashi, Y., Yamamoto, Y., Kato, T., et al. (2022) · International Journal of Urology · doi:10.1111/iju.14816 · Cited by 17
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 17
Stensgaard, S., Thomsen, A., Helstrup, S., Meldgaard, P., & Sørensen, B. S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-818 · Cited by 17
Clinical applications of cell-free DNA-based liquid biopsy analysis
Yazaki, S., Tokura, M., Aiba, H., Kojima, Y., & Shiraishi, K. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102519 · Cited by 17
Boniface, C. T., & Spellman, P. T. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610103 · Cited by 17
Voss, M. H., Azad, A. A., Hansen, A. R., Gray, J. E., Welsh, S. J., Song, X., Kuziora, M., Meinecke, L., Blando, J. M., Achour, I., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4115 · Cited by 17
Marandino, L., Raggi, D., Calareso, G., Alessi, A., Colecchia, M., Martini, A., Briganti, A., Montorsi, F., Madison, R. W., Ross, J. S., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.04.001 · Cited by 17
Biomarkers and immunotherapy: where are we?
Fontsa, M. L., Padonou, F., & Willard-Gallo, K. E. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000891 · Cited by 16
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
ctDNA Analysis in ERBB2 -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Meric‐Bernstam, F., Raghav, K. P. S., Sweeney, C. J., Swanton, C., Spigel, D. R., Bose, R., Burris, H. A., Friedman, C. F., Espenschied, C. R., Grindheim, J. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2763 · Cited by 16
Zhong, J., Jiang, H., Liu, X., Liao, H., Xie, F., Shao, B., Jia, S., & Li, H. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07210-9 · Cited by 16
Wen, S. W. C., Nederby, L., Andersen, R. F., Hansen, T. S., Nyhus, C. H., Hilberg, O., Jakobsen, A. K. M., & Hansen, T. F. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02285-z · Cited by 16
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma
Nazha, B., Zhuang, T., Dada, H. I., Drusbosky, L. M., Brown, J. T., Ravindranathan, D., Carthon, B. C., Küçük, Ö., Goldman, J. M., Master, V. A., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac061 · Cited by 16
Chiang, A. C., Madison, R. W., Assaf, Z. J. F., Fine, A. D., Cao, Y., Gjoerup, O. V., Huang, Y., Jin, D. X., Hughes, J. D., Antic, V., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100829 · Cited by 16
State of the Art: ctDNA in Upper Gastrointestinal Malignancies
Labiano, I., Huerta, A. E., Arrazubi, V., Hernández-García, I., Mata, E., Gómez, D., Arasanz, H., Vera, R., & Alsina, M. (2023) · Cancers · doi:10.3390/cancers15051379 · Cited by 15
Ye, P. P., Viens, R., Shelburne, K. E., Langpap, S., Bower, X., Shi, J. J., Zhou, W., Wignall, J., Zhu, J. J., Woodward, B. D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-90013-3 · Cited by 15
Zollinger, D. R., Rivers, E., Fine, A. D., Huang, Y., Son, J., Kalyan, A., Gray, W., Baharian, G., Hammond, C., Ram, R. R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302129 · Cited by 15
Honoré, N., van der Elst, A., Dietz, A., van Marcke, C., Helaers, R., Mendola, A., Dahou, H., Marbaix, É., Poncin, R., Seront, E., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113372 · Cited by 15
Pecci, F., Thummalapalli, R., Alden, S. L., Ricciuti, B., Alessi, J. V., Elkrief, A., Rizvi, H. A., Wang, X., Jeng, M. Y., Egger, J. V., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2990 · Cited by 14
Self-citationRecent Advances in the Management of Anal Cancer
Upadhyay, L., Hartzell, M., Parikh, A. R., Strickland, M. R., Klempner, S. J., & Malla, M. (2023) · Healthcare · doi:10.3390/healthcare11233010 · Cited by 14
Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma
Grinspan, L. T., & Villanueva, A. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1748924 · Cited by 14
Sanz‐García, E., Genta, S., Chen, X., Ou, Q., Araújo, D. V., Razak, A. R. A., Hansen, A. R., Spreafico, A., Bao, H., Wu, X., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00509 · Cited by 14
Zhu, S., Wu, R., Liu, X., Xie, B., Xie, C., Li, S., Wu, Z., Zhang, Z., Tang, Z., & Gu, L. (2024) · Future Oncology · doi:10.1080/14796694.2024.2376513 · Cited by 14
Okusanya, Ó. O., Patilea-Vrana, G., Sireci, A. N., Iasonos, A. E., Davidson, B. A., Liu, J., Shord, S. S., LoRusso, P. M., & Yap, T. A. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1918 · Cited by 14
Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer
Al-Obeidi, E., Riess, J. W., Malapelle, U., Rolfo, C. D., & Gandara, D. R. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.005 · Cited by 14
Molecular residual disease: A new clue for individualized approach in non‐small cell lung cancer
Zhang, J., Zhong, W., & Wu, Y.-L. (2023) · Medicine Advances · doi:10.1002/med4.11 · Cited by 14
Zhang, M., Zhang, G., Niu, Y., Zhang, G., Ji, Y., Yan, X., Zhang, X., Wang, Q., Jing, X., Wang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45769-z · Cited by 14
Reinmuth, N., Juan, Ó., Kowalski, D. M., Bryl, M., Kryzhanivska, A., Vicente, D., Horváth, Z., Gálffy, G., Csánky, E., Székely, Z. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0013 · Cited by 14
Gentzler, R. D., Guittar, J. L., Mitra, A., Iams, W. T., Driessen, T. M., Schwind, R. M., Stein, M. M., Kaneva, K., Hyun, S. W., Liu, Y., et al. (2024) · Oncology and Therapy · doi:10.1007/s40487-024-00287-2 · Cited by 14
Ponomaryova, A. A., RYKOVA, E. Y., Solovyova, A. I., Tarasova, A. S., Kostromitsky, D. N., Dobrodeev, А. Y., Afanasiev, S. A., & Чердынцева, Н. В. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512407 · Cited by 14
Impacts of ageing on the efficacy of CAR-T cell therapy
Qi, S., Li, J., Gu, X., Zhang, Y., Zhou, W., Wang, F., & Wang, W. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102715 · Cited by 13
Li, S., Yuan, T., Yuan, J., Zhu, B., & Chen, D. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06030-8 · Cited by 13
Rolfo, C. D., Khushman, M. M., Russo, A., Borea, R., Herrman, B., Wang, J., Liao, J., Espenschied, C. R., Gordon, S., Quinn, K., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100442 · Cited by 13
Imai, M., Nakamura, Y., Sunami, K., Kage, H., Komine, K., Koyama, T., Amano, T., Ennishi, D., Kanai, M., Kenmotsu, H., et al. (2022) · Cancer Science · doi:10.1111/cas.15504 · Cited by 13
Liu, L., Zong, S.-Y., Zhang, A., Ren, Y.-Y., Qi, B.-Q., Chang, L., Yang, W., Chen, X., Chen, Y.-M., Zhang, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2589 · Cited by 13
Han, W., Zhou, Y., Wang, Y., Liu, X., Sun, T., & Xu, J. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1591076 · Cited by 12
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Schram, A. M., Naqash, A. R., Haura, E. B., Riess, J. W., Ulahannan, S. V., Ou, S. I., Münster, P. N., Cheng, M. L., Gustafson, W. C., Bitman, B., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2112 · Cited by 12
Kasi, P. M., Chakrabarti, S., Sawyer, S. D., Krainock, M. R., Poklepovic, A. S., Ansstas, G., Maninder, M., Malhotra, M., Ensor, J., Gao, L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060342 · Cited by 12
Normanno, N., Caridi, V., Fassan, M., Avallone, A., Ciardiello, F., & Pinto, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00231 · Cited by 12
Rajdev, L. N., King, G. T., Lieu, C. H., Cohen, S. A., Pant, S., Uboha, N. V., Deming, D. A., Malla, M., Kasi, A., Klute, K. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00489 · Cited by 12
Cheng, L., Gao, G., Zhao, C., Wang, H., Yao, C. L., Yu, H., Yao, J., Li, F., Guo, L., Jian, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6108 · Cited by 12
Garralda, E., Abbott, C. W., Calahorro, A., Mirallas, O., Pugh, J. L., Moreno-Cárdenas, A. B., Keough, K. C., Galvao, V., Alonso, G., Olano, A. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2312 · Cited by 12
Liu, J., Fang, F., Yuan, W., Chen, T., Ji, W., Miao, X., Meng, Y., Chen, S., Tan, W., An, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0608 · Cited by 12
Surgically resectable nonsmall cell lung cancer: a contemporary approach
D'Amours, M.-F., Wu, F. T. H., Theisen-Lauk, O., Chan, E. K., McGuire, A., & Ho, C. (2024) · European Respiratory Journal · doi:10.1183/13993003.00332-2024 · Cited by 12
Fan, Y., Liu, Y., Wang, L., Cai, Y., Cao, W., Sun, W., Zou, X. N., Li, B., Zhang, Z., Cai, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104564 · Cited by 12
Browne, I. M., Pascual, J., Cutts, R. J., Kingston, B., Hrebien, S., Kilburn, L., Pearson, A., Moretti, L., Wardley, A. M., Macpherson, I. R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0651 · Cited by 12
Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010235 · Cited by 11
“The detected genomic alterations included single nucleotide variants (SNV), gene amplifications, fusions, short insertions/deletions (up to 70 base pairs), and splice site-disrupting events [38,39].”
Xu, Z., Zou, Z., Hao, X., Xing, P., & Li, J. (2023) · Cancer Innovation · doi:10.1002/cai2.49 · Cited by 11
The prospects and limitations of liquid biopsy utilization for clinical practice in Taiwan
Li, H.-Y., Chang, C.-C., Yang, Y.-H. S., Yao, C., Hsieh, C., & Chang, S.-H. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100290 · Cited by 11
Stinchcombe, T. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-530 · Cited by 11
Circulating tumor DNA in biliary tract cancers: A review of current applications
Teixeira, M. F., Borad, M. J., & Usón, P. L. S. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i10.107875 · Cited by 11
Recent advances in liquid biopsy for genitourinary cancers: A narrative review
Harrs, C., Pusala, S., Cheng, L., Jazayeri, S. B., & Li, R. (2025) · Histopathology · doi:10.1111/his.70047 · Cited by 11
Fu, X., Li, F., You, H., Xu, B., Wang, T., Qin, P., Han, L., Zhang, Y., Zhang, F., Zhao, L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-02597-5 · Cited by 11
Cortinovis, D. L., Malapelle, U., Pagni, F., Russo, A., Banna, G. L., Sala, E., & Rolfo, C. D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1067 · Cited by 11
Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now.
Stewart, T. F., Chalfin, H., Simon, N. I., Tan, A., Apolo, A. B., & McKay, R. R. (2024) · PubMed Central · doi:10.3233/blc-230105 · Cited by 11
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases
Desai, A. P., Pasquina, L. W., Nulsen, C., Keller-Evans, R. B., Mata, D. A., Tukachinsky, H., & Oxnard, G. R. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100140 · Cited by 10
Metadata
- Authors
- Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., Segal, N. H., Chaft, J. E., Hembrough, T., Barrett, J. C., & Hellmann, M. D.
- Affiliations
- 1Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, Maryland.
- Memorial Sloan Kettering Cancer Center (US)
- 3Early Oncology Statistics, AstraZeneca, Gaithersburg, Maryland.
- AstraZeneca (United States) (US)
- 5Division of Molecular Carcinogenesis and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
- Corresponding author
- Hellmann, Matthew D.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-12-01
- Volume
- 10
- Issue
- 12
- Pages
- 1842-1853
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8358981
- OpenAlex
- W3049083268
- Cited by
- 348
- References
- 53
- Citations by year
- 2026: 31 · 2025: 72 · 2024: 60 · 2023: 70 · 2022: 54 · 2021: 54 · 2020: 6
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- AstraZeneca (NCT01693562, NCT02087423, NCT02261220)
- Memorial Sloan Kettering Cancer Center (P30 CA008748)
- Damon Runyon Cancer Research Foundation (CI-98-18)
- Parker Institute for Cancer Immunotherapy
- NIH (T32-CA009207, K30-UL1TR00457)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- circulating tumor DNA, immune checkpoint blockade, durvalumab, tremelimumab, variant allele frequency, molecular response, prognostic factors, predictive biomarkers, overall survival, progression-free survival, objective response rate, pan-cancer analysis, CTLA-4 blockade
- MeSH terms
- Circulating Tumor DNA, Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.